Labcorp Launches Labcorp Plasma Detect Extending Leadership Into Molecular Residual Disease (MRD) Clinical Research
Portfolio Pulse from Benzinga Newsdesk
Labcorp has launched Labcorp Plasma Detect, a new solution for Molecular Residual Disease (MRD) clinical research, enhancing its precision oncology offerings. This addition builds on two existing liquid biopsy platforms, Labcorp Plasma Focus and Labcorp Plasma Complete, developed by PGDx, a Labcorp company. All solutions are performed in PGDx's CAP-accredited and CLIA-certified laboratory in Baltimore.
April 05, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Labcorp's launch of Labcorp Plasma Detect for MRD clinical research signifies an expansion in its precision oncology offerings, potentially strengthening its market position.
The introduction of Labcorp Plasma Detect, by enhancing Labcorp's precision oncology services, could attract more clinical research projects and partnerships, potentially increasing revenue and market share in the oncology sector. Given the growing importance of MRD in cancer treatment and monitoring, this move aligns with industry trends and customer needs.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90